Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: A new independent unfavourable prognostic biomarker

British Journal of Cancer

Volumn 87, Issue 7, 2002, Pages 763-771

  Hoffman, B R ^a,b   Katsaros, D ^c   Scorilas, A ^d   Diamandis, P ^a   Fracchioli, S ^c   Rigault de la Longrais, I A ^c   Colgan, T ^a,b   Puopolo, M ^c   Giardina, G ^e   Massobrio, M ^c   Diamandis, E P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TURIN   (Italy)

^d INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^e S ANNA HOSPITAL   (Italy)

Author keywords

Biomarker; Kallikrein 6; Ovarian cancer; Prognosis; Survival

Indexed keywords

BIOLOGICAL MARKER; KALLIKREIN; KALLIKREIN 6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; FLUOROMETRY; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; REGRESSION ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CELL EXTRACTS; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KALLIKREINS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 18644361962     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600533     Document Type: Article

References (45)

1. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R (1996) A novel protease homologue differentially expressed in breast and ovarian cancer. Mol Med 2: 624-636
2. Aunoble B, Sanches R, Didier E, Bignon YJ (2000) Major oncogenes and tumour suppressor genes involved in epithelial ovarian cancer. Int J Oncol 16: 567-576
3. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta L (1993) Molecular aspects of tumour cell invasion and metastasis. Cancer 71: 1368-1383
4. Cox DR (1972) regression tables and life tables. J R Stat Soc B 34: 187-202
5. Diamandis EP (1999) Prostate specific antigen - its usefulness in clinical medicine. Trends Endocrinol Metab 25: 14-16
6. Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV (2000a) The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 11: 54-60
7. Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, Nelson PS, Shiosaka S, Little S, Lilja H, Stenman U-H, Rittenhouse HG, Wain H (2000b) New nomenclature for the human tissue kallikrein gene family. Clin Chem 46: 1855-1858
8. Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S, Sotiropoulou G (2000c) Immunofluorometric assay of human kallikrein 6 (Zyme/Protease M/Neurosin) and preliminary clinical applications. Clin Biochem 33: 369-375
9. Diamandis EP, Yousef GM, Petraki C, Soosaipillai AR (2000d) Human kallikrein 6 as a biomarker of Alzheimer's disease. Clin Biochem 33: 663-667
10. Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P (2000e) Human kallikrein 6 (Zyme/Protease M/Neurosin): a new serum biomarker of ovarian cancer. Clin Biochem 33: 579-583
11. Duffy MJ (1992) Role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metasis 10: 145-155
12. Gatta G, Lasota MB, Verdecchia A (1998) Survival of European women with gynaecological tumours during the period 1978-1989. Eur J Cancer 34: 2218-2225
13. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V (1998) The role for NES1 serine protease as a novel tumour suppressor. Cancer Res 58: 4782-4786
14. Hirahara F, Miyagi E, Nagashima Y, Miyagi Y, Yasumitsu H, Koshikawa N, Nakatani Y, Nakazawa T, Udagawa K, Kitamura H, Minaguchi H, Miyazaki K (1998) Differential expression of trypsin in human ovarian cancinomas and low-malignant-potential tumours. Gynecol Oncol 68: 162-165
15. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
16. Kim H, Scorilas A, Katsaros D, Diamandis EP (2001) human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 84: 643-650
17. Kleiner DE, Stetler-Stevenson WG (1999) Matrix metalloproteinases and metastases. Cancer Chemother Pharmacol 43: S42-S51
18. Lambet-Messerlian GM (2000) Is inhibin a serum marker for ovarian cancer? Eur J Endocrinol 42: 331-333
19. Levesque MA, Clark GM, Diamandis EP (1998) Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 4: 1489-1497
20. Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, Dobbins JR., Wyrick T, Miller JR, MacKellar W, Hepburn D, Corvalan J, McClure D, Liu X, Stephenson D, Clemens J, Johnstone EM (1997) Zyme, a novel and potentially amyloidogenice nzyme cDNA isolated from Alzheimer's disease brain. J Biol Chem 272: 25135-25142
21. Liu XL, Wazer DE, Watanabe K, Band V (1996) Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 56: 3371-3379
22. Luo L-Y, Katsaros D, Scorilas A, Fracchioli S, Massobrio M, Howarth DJC, Diamandis EP (2001) Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 7: 2372-2379
23. Maggino T, Gadducci A (2000) Serum markers as prognostic factors in epithelial ovarian cancer: an overview. Eur J Gynaecol Oncol 21: 64-69
24. Magklara A, Scorilas A, Yousef GM, Katsaros D, Fracchioli S, Diamandis EP (2001) The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 7: 806-811
25. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170
26. Matrisian LM (1999) Cancer biology: extracellular proteinases in malignancy. Curr Biol 9: R776-R778
27. Menon U, Jacobs IJ (2000) Recent developments in ovarian cancer screening. Curr Opinion Obstet Gynecol 12: 39-42
28. Obiezu CV, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Rigault de la Longrais IA, Arisio R, Diamandis EP (2001) Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 7: 2380-2386
29. Ono K, Tanaka T, Tsunoda T, Kitahara O, Okamoto A, Ochiai K, Nakamura Y (2000) Identification by cDNA microarrayof genes involved in ovarian carcinogenesis. Cancer Res 60: 5007-5011
30. Riman T, Persson I, Staffin N (1998) Hormonal aspects of epothelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol 49: 695-707
31. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW (1998) Human kallikrein 2 (hK2) and prostate specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 35: 275-368
32. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, Hassell L, Baldwin RL, Karlan BY, Hood L (1999) Comparative hybridization of an array of 21, 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 238: 375-385
33. Shigemasa K, Tanimoto H, Parham GP, Parmley TH, Ohama K, O'Brien TJ (1999) Cydin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J Soc Gynecol Investig 6: 102-108
34. Shigemasa K, Underwood LJ, Beard J, Tanimoto H, Ohama K, Parmley TH, O'Brien TJ (2000) Overexpression of testisin, a serine protease expressed by testicular germ cells, in epithelial ovarian tumour cells. J Soc Gynecol Investig 7: 358-362
35. Suzuki S, Moore DH, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray JW (2000) An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 60: 5382-5385
36. Tanimoto H, Yan Y, Clarke J, Korourian S, Shigemasa K, Parmley TH, Parham GP, O'Brien TJ (1997) Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 57: 2884-2887
37. Tanimoto H, Underwood LJ, Shigemasa K, Yan MS, Clarke J, Parmley TH, O'Brien TJ (1999) The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumour cells. Cancer 86: 2074-2082
38. Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, O'Brien TJ (2001) Increased expression of protease M in ovarian tumours. Tumour Biol 22: 11-18
39. Underwood LJ, Tanimoto H, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ (1999) Cloning of tumour-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res 59: 4435-4439
40. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM (2001) Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Nat Acad Sci 98: 1176-1181
41. Woodhouse EC, Chuaqui RF, Liotta LA (1997) General mechanisms of metastasis. Cancer 80: 1529-1537
42. Yamashiro K, Tsuruoiko N, Kodama S, Tsujimoto M, Yamamura T, Tanaka T, Nakazato H, Yamaguchi N (1997) Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim Biophys Acta 1350: 11-14
43. Yousef GM, Diamandis EP (2001) The new human tissue kallikrein gene family: Structure, function and association to disease. Endocr Rev 22: 184-204
44. Yousef GM, Luo L-Y, Scherer SW, Sotiropoulou G, Diamandis EP (1999) Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics 62: 251-259
45. Yousef GM, Chang A, Diamandis EP (2000) Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem 275: 11891-11898